

**Table S5.** YM155 concentrations that reduce the viability of neuroblastoma cell lines by 50% (IC<sub>50</sub>, mean ± S.D., n = 3) in the absence or presence of the ABCB1 inhibitors verapamil (5 µM) or zosuquidar (1.25 µM) as indicated by MTT assay after 120h of incubation.

Cell line	YM155 IC <sub>50</sub> (nM)	+ verapamil (5 µM)		+ zosuquidar (1.25 µM)	
		verapamil alone	YM155 IC <sub>50</sub> (nM)	zosuquidar alone	YM155 IC <sub>50</sub> (nM)
CHP-134	2.64 ± 0.50	94 ± 13 <sup>1</sup>	1.64 ± 0.27 (1.6) <sup>2</sup>	105 ± 6 <sup>1</sup>	1.85 ± 0.34 (2.4)
GIMEN	33.74 ± 2.26	105 ± 3	52.90 ± 8.62 (0.6)	92 ± 7	50.87 ± 5.91 (0.7)
IMR-5	7.18 ± 1.04	109 ± 8	9.70 ± 1.97 (0.7)	104 ± 11	10.64 ± 2.80 (0.7)
IMR-5 <sup>r</sup> CARBO <sup>5000</sup>	8.55 ± 2.01	91 ± 16	7.80 ± 0.28 (1.1)	105 ± 8	27.01 ± 3.04 (0.3)
IMR-5 <sup>r</sup> CDDP <sup>1000</sup>	19.71 ± 5.70	88 ± 11	15.23 ± 4.21 (1.3)	100 ± 6	33.47 ± 6.84 (0.6)
IMR-5 <sup>r</sup> DOCE <sup>20</sup>	21549 ± 638	90 ± 7	149.01 ± 1.99 (145)	112 ± 2	13.63 ± 5.54 (1581)
IMR-5 <sup>r</sup> DOX <sup>20</sup>	116.31 ± 21.63	97 ± 9	17.60 ± 0.57 (6.6)	99 ± 8	13.45 ± 2.45 (8.6)
IMR-5 <sup>r</sup> ETO <sup>100</sup>	8.29 ± 3.95	95 ± 10	6.99 ± 2.79 (1.2)	97 ± 4	18.26 ± 3.19 (0.5)
IMR-5 <sup>r</sup> GEMCI <sup>20</sup>	7.08 ± 1.20	108 ± 6	7.90 ± 2.09 (0.9)	105 ± 8	12.73 ± 3.34 (0.6)
IMR-5 <sup>r</sup> MEL <sup>1000</sup>	11.10 ± 1.57	92 ± 8	6.63 ± 1.30 (1.7)	107 ± 6	12.80 ± 1.22 (0.9)
IMR-5 <sup>r</sup> OXALI <sup>4000</sup>	10.18 ± 2.69	96 ± 8	15.80 ± 1.77 (0.6)	110 ± 6	16.81 ± 2.71 (0.6)
IMR-5 <sup>r</sup> TOPO <sup>20</sup>	4.88 ± 1.72	100 ± 13	5.94 ± 1.31 (0.8)	101 ± 7	11.77 ± 3.95 (0.4)
IMR-5 <sup>r</sup> VCR <sup>10</sup>	472.94 ± 97.42	93 ± 8	13.05 ± 2.90 (36)	94 ± 5	19.35 ± 0.07 (24)
IMR-5 <sup>r</sup> VINB <sup>20</sup>	1608 ± 212	93 ± 7	9.34 ± 0.94 (172)	93 ± 6	10.05 ± 1.06 (160)
IMR-32	1.40 ± 0.35	102 ± 7	1.70 ± 0.41 (0.8)	101 ± 3	1.80 ± 0.23 (0.8)
IMR-32 <sup>r</sup> DOX <sup>20</sup>	35.63 ± 2.23	92 ± 15	1.75 ± 0.77 (20)	89 ± 13	0.94 ± 0.08 (38)
IMR-32 <sup>r</sup> ETO <sup>100</sup>	1.53 ± 0.13	90 ± 5	1.60 ± 0.27 (1.0)	104 ± 6	3.55 ± 0.21 (2.2)
IMR-32 <sup>r</sup> GEMCI <sup>20</sup>	2.16 ± 0.22	105 ± 8	1.15 ± 0.05 (1.9)	107 ± 11	4.20 ± 0.45 (0.5)
IMR-32 <sup>r</sup> OXALI <sup>800</sup>	0.60 ± 0.02	99 ± 8	0.71 ± 0.08 (0.8)	105 ± 12	1.18 ± 0.07 (1.7)
IMR-32 <sup>r</sup> TOPO <sup>7.5</sup>	0.45 ± 0.06	97 ± 10	0.61 ± 0.07 (0.7)	101 ± 2	0.97 ± 0.04 (0.5)
LAN-6	248.08 ± 32.90	99 ± 8	46.75 ± 2.33 (5.3)	103 ± 5	24.35 ± 1.06 (10.2)
NB-S-124	76.66 ± 6.51	103 ± 6	12.52 ± 1.16 (6.1)	110 ± 8	3.20 ± 0.40 (24.0)
NGP	12.48 ± 3.01	91 ± 8	17.35 ± 4.97 (0.7)	109 ± 2	24.95 ± 0.21 (0.5)
NGP <sup>r</sup> CARBO <sup>5000</sup>	112.33 ± 5.0	112 ± 9	76.10 ± 3.17 (1.5)	107 ± 5	158.24 ± 9.34 (0.7)
NGP <sup>r</sup> CDDP <sup>1000</sup>	13.00 ± 0.42	104 ± 5	19.61 ± 1.35 (0.7)	101 ± 18	17.80 ± 0.97 (0.7)
NGP <sup>r</sup> DACARB <sup>18</sup>	20.59 ± 1.84	107 ± 2	26.26 ± 4.77 (0.8)	103 ± 7	41.90 ± 5.27 (0.5)
NGP <sup>r</sup> DOX <sup>20</sup>	306.90 ± 78.5	92 ± 6	5.52 ± 0.35 (56)	90 ± 2	0.70 ± 0.04 (438)
NGP <sup>r</sup> ETO <sup>400</sup>	59.20 ± 11.40	98 ± 16	50.14 ± 16.45 (1.2)	98 ± 3	39.12 ± 7.87 (1.5)
NGP <sup>r</sup> GEMCI <sup>20</sup>	41.55 ± 6.13	94 ± 13	73.43 ± 16.41 (0.6)	105 ± 12	10.50 ± 1.34 (4.0)
NGP <sup>r</sup> MEL <sup>3000</sup>	26.10 ± 3.86	99 ± 10	24.34 ± 1.76 (1.1)	108 ± 9	18.75 ± 4.64 (1.4)
NGP <sup>r</sup> OXALI <sup>4000</sup>	6.93 ± 0.28	102 ± 8	12.25 ± 2.78 (0.6)	101 ± 12	8.21 ± 1.04 (0.8)
NGP <sup>r</sup> VCR <sup>20</sup>	6986.25 ± 715	100 ± 10	157.60 ± 11.79 (44)	106 ± 15	16.20 ± 1.74 (431)
NLF	4.18 ± 0.27	93 ± 8	4.55 ± 0.32 (0.9)	99 ± 5	2.85 ± 0.14 (1.5)

NLF <sup>r</sup> CARBO <sup>5000</sup>	340.51 ± 34.47	95 ± 7	196.4 ± 17.9 (1.7)	104 ± 8	569.90 ± 76.7 (0.6)
NLF <sup>r</sup> CDDP <sup>500</sup>	12.58 ± 5.39	103 ± 6	20.10 ± 1.84 (0.6)	101 ± 15	24.84 ± 3.25 (0.5)
NLF <sup>r</sup> DOCE <sup>200</sup>	21.60 ± 5.98	99 ± 4	8.58 ± 0.76 (2.5)	109 ± 9	3.93 ± 0.17 (5.5)
NLF <sup>r</sup> DOX <sup>40</sup>	34.88 ± 4.33	110 ± 18	31.15 ± 0.78 (1.1)	98 ± 6	59.81 ± 1.41 (0.6)
NLF <sup>r</sup> ETO <sup>100</sup>	7.40 ± 0.54	108 ± 5	9.35 ± 0.50 (0.8)	97 ± 12	11.05 ± 0.63 (0.7)
NLF <sup>r</sup> GEMCI <sup>20</sup>	1.84 ± 0.47	94 ± 10	2.30 ± 0.14 (0.8)	108 ± 13	2.65 ± 0.50 (0.7)
NLF <sup>r</sup> RINO <sup>1000</sup>	6.93 ± 0.71	98 ± 9	3.83 ± 0.64 (1.8)	89 ± 17	10.96 ± 1.37 (0.6)
NLF <sup>r</sup> MEL <sup>3000</sup>	15.36 ± 3.20	100 ± 7	12.70 ± 0.14 (1.2)	105 ± 11	27.45 ± 0.99 (0.6)
NLF <sup>r</sup> OXALI <sup>4000</sup>	33.67 ± 2.67	102 ± 11	30.05 ± 2.33 (1.1)	96 ± 3	51.25 ± 13.51 (0.7)
NLF <sup>r</sup> VCR <sup>10</sup>	334.45 ± 21.6	90 ± 14	74.70 ± 19.13 (4.5)	99 ± 18	295.8 ± 34.9 (1.1)
NLF <sup>r</sup> VINB <sup>10</sup>	38.10 ± 12.02	95 ± 6	36.74 ± 7.24 (1.0)	106 ± 8	65.67 ± 11.06 (0.6)
SHEP	10.15 ± 0.84	88 ± 5	3.92 ± 0.11 (2.6)	95 ± 11	3.20 ± 0.14 (3.2)
SHEP <sup>r</sup> CDDP <sup>1000</sup>	30.83 ± 2.24	105 ± 3	5.50 ± 0.37 (5.6)	110 ± 8	5.27 ± 0.17 (5.9)
SHEP <sup>r</sup> ETO <sup>100</sup>	20.24 ± 10.16	101 ± 14	5.35 ± 0.17 (3.8)	103 ± 12	5.11 ± 0.83 (4.0)
SHEP <sup>r</sup> VCR <sup>10</sup>	20.95 ± 1.45	99 ± 9	8.31 ± 1.55 (2.5)	107 ± 13	3.64 ± 0.09 (5.8)
SK-N-AS	3.55 ± 0.21	107 ± 3	1.01 ± 0.26 (3.5)	97 ± 9	1.31 ± 0.11 (2.7)
SK-N-SH	74.94 ± 19.52	91 ± 12	6.80 ± 0.83 (11.0)	94 ± 6	1.72 ± 0.15 (43.6)
UKF-NB-2	4.18 ± 0.27	93 ± 8	4.55 ± 0.32 (0.9)	99 ± 5	2.85 ± 0.14 (1.5)
UKF-NB-2 <sup>r</sup> CARBO <sup>2000</sup>	318.21 ± 42.68	106 ± 14	114.7 ± 14.6 (2.8)	113 ± 19	7.67 ± 1.29 (41.5)
UKF-NB-2 <sup>r</sup> OXALI <sup>600</sup>	3.25 ± 0.64	89 ± 10	5.90 ± 0.97 (0.6)	109 ± 16	3.00 ± 0.73 (1.1)
UKF-NB-3	0.49 ± 0.10	90 ± 9	0.61 ± 0.13 (0.8)	102 ± 6	0.74 ± 0.10 (0.7)
UKF-NB-3 <sup>r</sup> CARBO <sup>2000</sup>	155.36 ± 24.6	101 ± 8	20.50 ± 3.79 (7.6)	88 ± 11	9.20 ± 1.62 (16.9)
UKF-NB-3 <sup>r</sup> CDDP <sup>1000</sup>	5.32 ± 1.21	93 ± 18	13.85 ± 1.42 (0.4)	102 ± 6	18.55 ± 1.34 (0.3)
UKF-NB-3 <sup>r</sup> DOCE <sup>10</sup>	469.60 ± 113.08	105 ± 10	32.60 ± 7.85 (14.4)	113 ± 9	0.50 ± 0.04 (939)
UKF-NB-3 <sup>r</sup> DOX <sup>20</sup>	15,700.05 ± 1,019	92 ± 7	34.40 ± 11.73 (456)	107 ± 15	1.70 ± 0.49 (9235)
UKF-NB-3 <sup>r</sup> ETO <sup>200</sup>	7.97 ± 0.13	98 ± 17	4.40 ± 0.27 (1.8)	101 ± 14	5.00 ± 0.14 (1.6)
UKF-NB-3 <sup>r</sup> GEMCI <sup>10</sup>	0.40 ± 0.01	91 ± 12	0.50 ± 0.04 (0.8)	104 ± 18	0.50 ± 0.06 (0.8)
UKF-NB-3 <sup>r</sup> OXALI <sup>4000</sup>	1.80 ± 0.78	95 ± 9	0.97 ± 0.09 (1.9)	105 ± 10	1.08 ± 0.14 (1.7)
UKF-NB-3 <sup>r</sup> TOPO <sup>20</sup>	7.40 ± 0.71	103 ± 5	2.00 ± 0.05 (3.7)	109 ± 13	5.13 ± 0.84 (1.4)
UKF-NB-3 <sup>r</sup> VCR <sup>10</sup>	26.59 ± 6.37	94 ± 5	1.95 ± 0.28 (13.6)	115 ± 14	1.35 ± 0.21 (19.7)
UKF-NB-6	0.65 ± 0.09	101 ± 4	0.58 ± 0.07 (1.1)	107 ± 6	0.57 ± 0.07 (1.1)
UKF-NB-6 <sup>r</sup> CARBO <sup>2000</sup>	16.83 ± 1.62	97 ± 13	13.31 ± 2.79 (1.3)	103 ± 12	7.27 ± 2.17 (2.3)
UKF-NB-6 <sup>r</sup> CDDP <sup>2000</sup>	79.93 ± 7.14	94 ± 11	21.72 ± 1.87 (3.7)	105 ± 2	13.30 ± 6.47 (6.0)
UKF-NB-6 <sup>r</sup> DOCE <sup>10</sup>	14.33 ± 4.08	92 ± 14	5.48 ± 1.01 (2.6)	101 ± 18	1.83 ± 0.03 (7.8)
UKF-NB-6 <sup>r</sup> DOX <sup>20</sup>	11.80 ± 1.56	99 ± 16	1.35 ± 0.35 (8.7)	99 ± 14	0.60 ± 0.07 (19.7)
UKF-NB-6 <sup>r</sup> ETO <sup>200</sup>	3.60 ± 0.01	101 ± 19	0.50 ± 0.04 (7.2)	104 ± 7	1.24 ± 0.47 (2.9)
UKF-NB-6 <sup>r</sup> GEMCI <sup>10</sup>	2.10 ± 0.84	110 ± 3	1.54 ± 0.10 (1.4)	106 ± 9	1.36 ± 0.61 (1.5)
UKF-NB-6 <sup>r</sup> OXALI <sup>4000</sup>	5.34 ± 0.71	96 ± 10	3.47 ± 0.07 (1.5)	89 ± 7	3.04 ± 0.73 (1.8)
UKF-NB-6 <sup>r</sup> TOPO <sup>20</sup>	3.47 ± 0.81	91 ± 4	1.00 ± 0.08 (3.5)	107 ± 10	1.35 ± 0.78 (2.6)

UKF-NB-6\VCR <sup>10</sup>	49.30 ± 2.24	104 ± 5	3.60 ± 0.12 (13.7)	103 ± 16	0.70 ± 0.10 (70.4)
UKF-NB-6\VINOR <sup>40</sup>	228.52 ± 41.54	95 ± 8	8.63 ± 1.01 (26.5)	100 ± 19	0.74 ± 0.06 (309)

<sup>1</sup> effect of verapamil (5µM) or zosuquidar (1.25µM) alone on cell viability presented as percentage (mean ± S.D.) relative to untreated control

<sup>2</sup> fold sensitisation (YM155 IC<sub>50</sub>/ YM155 IC<sub>50</sub> in the presence of ABCB1 inhibitor)